Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea

Scandinavian Journal of Gastroenterology

Volumn 51, Issue 7, 2016, Pages 835-841

  Wagner, Michael ^a   Sjöberg, Klas ^b   Vigren, Lina ^c   Olesen, Martin ^b   Benoni, Cecilia ^b   Toth, Ervin ^b   Carlson, Marie ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Ystad Hospital   (Sweden)

Author keywords

Collagenous colitis; eosinophil; eosinophil cationic protein; eosinophil protein X; fecal markers

Indexed keywords

CALGRANULIN; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PROTEIN X; MYELOPEROXIDASE; BIOLOGICAL MARKER; EOSINOPHIL GRANULE PROTEIN;

ADULT; AGED; ARTICLE; CHRONIC DIARRHEA; CHRONIC NON BLOODY DIARRHEA; CLINICAL EVALUATION; COLLAGENOUS COLITIS; COLON BIOPSY; COLONOSCOPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FECES LEVEL; FEMALE; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTIC COLITIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC COLITIS; PATIENT REFERRAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS; ADOLESCENT; BIOPSY; BLOOD; CHEMISTRY; CHRONIC DISEASE; COLITIS, COLLAGENOUS; DIARRHEA; FECES; GASTROINTESTINAL HEMORRHAGE; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BIOPSY; CHRONIC DISEASE; COLITIS, COLLAGENOUS; COLONOSCOPY; DIARRHEA; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL GRANULE PROTEINS; EOSINOPHIL-DERIVED NEUROTOXIN; FECES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84958051030     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2016.1141432     Document Type: Article

References (38)

1. P.D.Thomas, A.Forbes, J.Green,. Guidelines for the investigation of chronic diarrhoea, 2nd ed. Gut. 2003;52:v1–v15.
2. C.Tysk, J.Bohr, N.Nyhlin,. Diagnosis and management of microscopic colitis. World J Gastroenterol. 2008;14:7280–7288.
3. O.H.O’Mahony, M.Burgoyne, J.J.Going Specific histological abnormalities are more likely in biopsies of endoscopically normal large bowel after the age of 60 years. Histopathology. 2012;61:1209–1213.
4. A.Hotouras, P.Collins, W.Speake,. Diagnostic yield and economic implications of endoscopic colonic biopsies in patients with chronic diarrhoea. Colorectal Dis. 2012;14:985–988.
5. I.F.Yusoff, D.G.Ormonde, N.E.Hoffman Routine colonic mucosal biopsy and ileoscopy increases diagnostic yield in patients undergoing colonoscopy for diarrhea. J Gastroenterol Hepatol. 2002;17:276–280.
6. A.Lasson, A.Kilander, P.O.Stotzer Diagnostic yield of colonoscopy based on symptoms. Scand J Gastroenterol. 2008;43:356–362.
7. V.Misra, S.P.Misra, M.Dwivedi,. Microscopic colitis in patients presenting with chronic diarrhea. Indian J Pathol Microbiol. 2010;53:15–19.
8. M.Olesen, S.Eriksson, J.Bohr,. Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993–1998. Gut. 2004;53:346–350.
9. D.S.Pardi, E.V.LoftusJr, T.C.Smyrk,. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut. 2007;56:504–508.
10. S.Vermeire, G.Van Assche, P.Rutgeerts Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–431.
11. C.G.Peterson, E.Eklund, Y.Taha,. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97:1755–1762.
12. C.G.Peterson, P.Sangfelt, M.Wagner,. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest. 2007;67:810–820.
13. M.Wagner, C.G.Peterson, P.Ridefelt,. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14:5584–5589 (discussion 5588).
14. F.Costa, M.G.Mumolo, M.Bellini,. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642–647.
15. J.Langhorst, S.Elsenbruch, T.Mueller,. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis. 2005;11:1085–1091.
16. A.G.Røseth, E.Aadland, J.Jahnsen,. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176–180.
17. J.Tibble, K.Teahon, B.Thjodleifsson,. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47:506–513.
18. J.A.Tibble, G.Sigthorsson, S.Bridger,. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15–22.
19. G.D’Haens, M.Ferrante, S.Vermeire,. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.
20. S.Wildt, J.J.Rumessen, C.Csillag,. Cyclooxygenase-2 immunoreactivity in collagenous colitis. APMIS. 2009;117:500–506.
21. M.Wagner, C.G.Peterson, I.Stolt,. Fecal eosinophil cationic protein as a marker of active disease and treatment outcome in collagenous colitis: a pilot study. Scand J Gastroenterol. 2011;46:849–854.
22. H.Lettesjö, T.Hansson, C.Peterson,. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. Scand J Gastroenterol. 2006;41:54–59.
23. M.Wagner, M.Lampinen, P.Sangfelt,. Budesonide treatment of patients with collagenous colitis restores normal eosinophil and T-cell activity in the colon. Inflamm Bowel Dis. 2010;16:1118–1126.
24. P.Venge, J.Byström, M.Carlson,. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 1999;29:1172–1186.
25. S.P.Hogan, H.F.Rosenberg, R.Moqbel,. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008;38:709–750.
26. M.Komraus, H.Wos, S.Wiecek,. Usefulness of faecal calprotectin measurement in children with various types of inflammatory bowel disease. Mediators Inflamm. 2012;2012:608249.
27. J.K.Larsson, K.Sjöberg, L.Vigren,. Chronic non-bloody diarrhoea: a prospective study in Malmö, Sweden, with focus on microscopic colitis. BMC Res Notes. 2014;7:236.
28. M.Olesen, S.Eriksson, J.Bohr,. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut. 2004;53:536–541.
29. P.Pavlidis, F.J.Chedgy, J.A.Tibble Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scand J Gastroenterol. 2013;48:1048–1054.
30. A.C.von Roon, L.Karamountzos, S.Purkayastha,. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803–813.
31. M.R.Konikoff, L.A.Denson Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524–534.
32. A.G.Røseth Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis. 2003;35:607–609.
33. T.Sipponen, P.Kärkkäinen, E.Savilahti,. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221–1229.
34. T.Sipponen, E.Savilahti, K.L.Kolho,. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40–46.
35. B.Johne, M.K.Fagerhol, T.Lyberg,. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997;50:113–123.
36. T.Olofsson, I.Olsson, P.Venge,. Serum myeloperoxidase and lactoferrin in neutropenia. Scand J Haematol. 1977;18:73–80.
37. Y.Taha, M.Carlson, M.Thorn,. Evidence of local eosinophil activation and altered mucosal permeability in collagenous colitis. Dig Dis Sci. 2001;46:888–897.
38. P.Sangfelt, M.Carlson, M.Thörn,. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Am J Gastroenterol. 2001;96:1085–1090.